Major pharmaceutical companies are seeing gains as the U.S. government considers reducing discounts under the 340B drug pricing program.

Top bankers indicate that while the biotech IPO window is beginning to open, mergers and acquisitions by large pharmaceutical companies remain the primary driver of dealmaking, fueled by the need to replenish drug pipelines ahead of patent expirations.

Advances are transforming cancer treatment, but questions are being raised about whether major pharmaceutical companies can afford to implement these revolutionary changes. The financial implications of new therapies pose a significant challenge for the industry.

An article argues that the pursuit of a cancer cure should not be constrained by the interests and influence of large pharmaceutical companies.

Major pharmaceutical companies are increasingly turning their attention to China as a source for the newest drug ideas and innovations.

As mergers and acquisitions in the oncology sector intensify, five biotech companies are identified as potential targets for acquisition by larger pharmaceutical firms.

An official from the Federal Trade Commission (FTC) stated that the agency is monitoring how major pharmaceutical companies are reacting to upcoming patent expirations.

Watch: RFK Jr. Destroys Media's Trump Caricature, Celebrates Epic Win On Drug Prices Authored by Steve Watson via Modernity.news, HHS Secretary Robert F. Kennedy Jr. delivered a powerful takedown of the fake news narrative surrounding President Trump, exposing the blatant lies and highlighting the administration’s groundbreaking success in driving down prescription drug costs—a move that puts American families first and crushes Big Pharma’s grip. Kennedy’s remarks come amid t...

The Wall Street Journal likens the disruptive effect of Ozempic on the pharmaceutical industry to the 'Napster moment' for music, highlighting its significant market impact.

The pharmaceutical sector is increasingly optimistic about the future of weight-loss treatments, with a significant shift from injectable medications to more accessible pill forms, potentially expanding the market to $200 billion by the decade's end.

Tulsi Gabbard has released what she claims is evidence suggesting Dr. Anthony Fauci lied to Congress regarding the funding of "risky" coronavirus research linked to Big Pharma.

Biotech mergers and acquisitions are experiencing a strong start in 2026, poised for their best year since before the Covid-19 pandemic, driven by looming patent cliffs, buoyant public markets, and Big Pharma's pipeline expansion efforts.

An analysis explores whether Bristol Myers Squibb represents the best value investment among major pharmaceutical companies. The article likely delves into the company's financials, pipeline, and market position.

Big Pharma companies are increasingly focusing on smaller acquisitions and disciplined pricing, a trend that is proving to be advantageous for a wider range of biotech firms.

Major pharmaceutical companies involved with COVID vaccines were compelled to discontinue a new research study because of insufficient participant enrollment.

Ireland has become the world's third-largest exporter of pharmaceuticals, with medicines accounting for about 20% of its GDP, raising concerns about the risks associated with this dependency amid potential tariffs.

AP Shills For Big Pharma Antidepressants With 'Bewildering' Hit Piece Check this out... The Trump FDA's top drug regulator, Dr.

Big pharma has emerged from its 2025 paralysis with plenty of firepower

How Ozempic Brought a Napster Moment to Big Pharma  The Wall Street Journal

The weight-loss drug market is rapidly expanding globally, with a shift from injections to pills and intense competition between pharmaceutical giants like Novo Nordisk and Eli Lilly. Regulatory scrutiny is also impacting new product offerings in this lucrative sector.

JPMorgan bankers report that mergers and acquisitions in the pharmaceutical sector continue to outpace initial public offerings in the biotechnology industry.

An analysis highlights the five hottest biotech hunting grounds for Big Pharma, identifying the category leaders in these promising areas for pharmaceutical innovation and investment.

Dozens of UK Members of Parliament are opposing Health Secretary Wes Streeting's move to grant himself power to dictate NHS drug prices, raising concerns about legality and potential benefits for big pharmaceutical companies.

Major pharmaceutical companies are focusing on smaller deals, a strategic shift that is proving advantageous for the biotechnology sector.

Poolbeg Pharma's CEO stated that the recent patent win for POLB-001 significantly strengthens the company's potential for partnerships with major pharmaceutical companies.

AbbVie is highlighted as the only big pharma stock considered a 'buy-and-never-sell' option by an analyst.

An analysis suggests that pharmaceutical giant Novartis could be a stable, long-term core holding for investors.